Latest New Zealand News

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Critical Resources (ASX:CRR) spotlighted its multi-commodity pipeline and breakthrough battery cooling technology at the July 2026 TechKnow Invest Roadshow, highlighting exploration progress and exclusive global licensing deals.

Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.

Australian Foundation Investment Company (ASX:AFI) posted a 3% increase in net profit for FY26, holding dividends steady with a special payout amid portfolio underperformance against the ASX 200.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Fletcher Building has confirmed the release of government grant funds to Golden Bay Cement, enabling the purchase of New Zealand Units that underpin the plant's operation through 2040 and safeguard over 600 jobs in Whangarei.

Spark New Zealand restructures into Connectivity and Digital Services divisions, initiating a strategic review of its Digital Services arm to explore shareholder value maximisation. Leadership changes accompany the move, while FY26 guidance remains steady.

Critical Resources identified 14 pegmatite bodies at Mavis Lake’s Corona Field and confirmed high-grade tungsten and gold systems in New Zealand, while progressing its solid-state lithium-ion battery technology to full-format pouch cells.

Supply Network Limited has reported a strong preliminary FY2026 with $403.1 million in sales and a 44-cent fully franked final dividend, reflecting solid profit growth despite Middle East disruptions. The company is advancing major branch expansions and IT upgrades to fuel future growth.

Change Financial has delivered strong FY26 results with revenue up 21% and underlying EBITDA soaring 17-fold, driven by scaling of its Vertexon PaaS platform and expanding client base.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

FINEOS Corporation Holdings PLC reported a solid €39 million cash balance for Q2 2026 despite a 23% drop in client receipts due to timing. The company locked in a significant 10-year deal with OneAmerica Financial and maintained its FY26 revenue guidance between €147m and €152m.